OPK: Transitioning to a therapeutics-focused model with innovative multi-specific assets and strong partnerships
The company is shifting from diagnostics to therapeutics, highlighted by ModeX's unique multi-specific antibody platform and a robust pipeline in oncology, immunology, and infectious diseases. Strategic collaborations, strong capital allocation, and upcoming clinical milestones position it for sign…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.